A Case of Nasal/Paranasal Metastatic Renal Cell Carcinoma with VEGF Targeted Therapy

• Kumai Takumi

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

• Takahara Miki

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

• Yoshida Saeko

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

• Nagato Toshihiro

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

• Hayashi Tatsuya

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

• Harabuchi Yasuaki

  Department of Otolaryngology, Head and Neck Surgery, Asahikawa Medical University

抄録

Renal cell carcinoma (RCC) occasionally metastasizes to a variety of regions including bone and liver, but nasal and paranasal sinal metastases are rare. No standard treatment currently exists, because of the small number of cases, so treatment varies for each patient. Sorafenib is a novel small molecular inhibitor of several kinases for malignancy, especially for RCC and hepatocellular carcinoma. We report herein on a case of nasal and paranasal metastatic RCC treated with VEGF targeted therapy (sorafenib) and radiotherapy.<br>

収録刊行物

• 耳鼻咽喉科臨床　補冊

  耳鼻咽喉科臨床　補冊 137 (0), 52-53, 2013

  耳鼻咽喉科臨床学会

キーワード

• VEGF
• renal cell cancer
• sorafenib
• metastatic tumor

詳細情報

• CRID: 1390282679302836992
• NII論文ID: 130004558714
• DOI: 10.5631/jibirinsuppl.137.52
• ISSN: 21851557
• ISSN: 09121870
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可